Amanda Cass, PharmD, BCPS, BCOP, discusses strategies to manage the diarrhea that may occur as an adverse effect in patients treated with EGFR TKIs.
Amanda Cass, PharmD, BCPS, BCOP
Advertisement
Articles by Amanda Cass, PharmD, BCPS, BCOP
Advertisement
Latest Updated Articles
Dr. Cass on Managing Diarrhea in Patients Treated With EGFR TKIsOctober 21st 2022
Advertisement
Advertisement
Trending on OncLive
1
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
2
China’s NMPA Approves Iza-Bren for Pretreated Recurrent/Metastatic ESCC
3
Improved Outcomes for High-Risk CLL Remain Key Focus for Continued Development of Fixed-Duration Regimens
4
FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
5